Andrew David Fesnak, MD

Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Call 800-789-7366
Penn Medicine Provider

About me

  • Associate Professor of Clinical Pathology and Laboratory Medicine

My education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Fesnak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Mackey S, Dai A, Herbst-Nowrouzi F, Fesnak A, Siegel D, Plesa G Epitope-edited Hematopoietic Stem Cells and CAR T Cells Targeting Pan-hematologic Antigen CD45 Induce Conformational Changes That Affect Flow Cyotmetry Specificity in Clinical Product Characterization with Specific Antibody Paratope , Cytotherapy, 28(5 Supplement): 2026

Wang Y, McKenna D, Spitzer T, Brunker P, Nedelcu E, Fesnak A, Celluzzi C, DiGuardo M, Jacob EK Training in cell and gene therapy manufacturing: Unmet needs and arguments for graduate medical education , Transfusion, 66(1): 2026,259-265

Verschraegen CF, Hashibe M, Neill US, Pirl W, Hexner EO, O'Connell A; NASDC Consortium NCI Awardee Skills Development Consortium (NASDC): a Successful Novel Educational Effort to Maintain Early Academic Competitiveness: PART 1-Overview of the NASDC Coordinating Center , J Cancer Educ: 2025

Petrella J, Dai A, Mackey S, Correa A, Brennan AL, Fesnak A, Siegel D, Plesa G Feasibility of Releasing Fresh CART Cell Products for Infusion Based On Studying Product Post-Harvest Stability , Cytotherapy, 27(5): 2025,2

Fesnak, A T Cell and Related Immunotherapies , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024

Fesnak, A Gene Therapy , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024

Mackey S, Dai A, Davis MM, Fesnak A, Siegel D, Plesa G Flow Cytometry Case Studies Illustrating Comprehensive Approach Required For Developing, Optimizing, And Implementing Multicolor Panels For The Manufacturing And Release Of Investigational Cell Therapy Products At UPenn , Cytotherapy, 26(6): 2024,S137-S138

Mack EA, Dougher MC, Ginda AM, Cahill C, Murter M, Schell K, Tanhehco YC, Bhoj VG, Fesnak AD, Siegel DL, Kambayashi T, Aqui NA, O'Doherty U Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis , Blood, 143(11): 2024,1049-1054

Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy , Cytotherapy, 25(12): 2023,1370-1379

Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products , Cytotherapy, 25(6): 2023,S9

View all publications